Skip to the content
VYNE Therapeutics
Rooted in Innovation
About Us
About VYNE
®
Our Mission
Who We Are
Leadership
Board of Directors
Corporate Responsibility
Pipeline
Pipeline Overview
InhiBET™ BET Inhibitor Platform
VYN201
VYN202
Careers
Investors & Media
Investor Overview
Stock Information
Press Releases
Events & Presentations
In the News
ES&G / Culture
Corporate Governance
Filings & Financials
Contact Us
Search
Menu
Search for:
Search
Close search
Close
About Us
About VYNE
®
Our Mission
Who We Are
Leadership
Board of Directors
Corporate Responsibility
Pipeline
Pipeline Overview
InhiBET™ BET Inhibitor Platform
VYN201
VYN202
Careers
Investors & Media
Investor Overview
Stock Information
Press Releases
Events & Presentations
In the News
ES&G / Culture
Corporate Governance
Filings & Financials
Contact Us
SEC Filing: Form 8-K
March, 07 2022
Current report
Post date
March 7, 2022
Read More
SEC Filing: Form 8-K
March, 04 2022
Current report
Post date
March 4, 2022
Read More
SEC Filing: Form 8-K
March, 04 2022
Current report
Post date
March 4, 2022
Read More
SEC Filing: Form 8-K
March, 04 2022
Current report
Post date
March 4, 2022
Read More
SEC Filing: Form 8-K
January, 19 2022
Current report
Post date
January 19, 2022
Read More
SEC Filing: Form 8-K
January, 19 2022
Current report
Post date
January 19, 2022
Read More
Load More
Nothing left to load.
←
Previous page
Next page
→
×
You Are Leaving VYNETherapeutics.com
Return to
VYNE Therapeutics
Continue to
Amzeeq.com
close
You Are Leaving VYNETherapeutics.com
Return to
VYNE Therapeutics
Continue to
Zilxi.com
close
VYNE Therapeutics
VYNE Therapeutics